ストックスクリーナーアプリを入手
23.99
1.56%
-0.38
アフターアワーズ：
24.10
0.11
+0.46%
Beam Therapeutics Inc (BEAM) 最新ニュース
Beam Therapeutics faces securities fraud probe after clinical trial safety concerns cause stock to drop 9.5%. - Pluang
Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit? - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc.BEAM - PR Newswire
Beam Therapeutics Inc. (BEAM) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
Beam Therapeutics at cantor conference: base editing lead comes into focus - Investing.com Canada
Cathie Wood’s ARK sells Alphabet stock, buys Meta and Beam Therapeutics - Investing.com
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com India
Transcript : Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01 - marketscreener.com
Why (BEAM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $80 - Moomoo
BEAM Stock Price, Quote & Chart - ChartMill
BEAM Reiterated by Wedbush -- Price Target Maintained at $65 - GuruFocus
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $43 - Moomoo
BEAM Looks 14.6% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics at Wells Fargo conference: base editing gains ground By Investing.com - Investing.com India
Beam drops after updating Phase 1/2 trial data for gene-editing drug - Seeking Alpha
3 Promising Genomics Stocks in the Spotlight in 2026 - TradingView
BEAM - Finviz
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment - Yahoo Finance
Beam Therapeutics reports BEAM-302 AATD trial update - grafa.com
BEAM Looks 26.9% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 - The Manila Times
A single dose pushed a protective protein above its threshold in Beam Therapeutics' trial - Stock Titan
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
BEAM Should I Buy - Intellectia AI
Beam Therapeutics appoints Eric Foster as CCO - The Pharma Letter
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com Nigeria
Beam Therapeutics names Eric Foster as chief commercial officer - Investing.com
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer - Barchart.com
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences - news.futunn.com
Three Beam Therapeutics talks will be webcast from Boston and New York - Stock Titan
Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb - Yahoo Finance
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains - TradingView
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.2%Here's What Happened - MarketBeat
Beam (BEAM) Range: Posts a 1.62% Loss to $28.60 on the Day; Current Setup: $27.17 and $30.03 Define the Nearby Reference Levels in the Available RecordDebt Free Companies - Vinanet
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Beam (BEAM) Latest Quarter: EPS Falls Short of Its Estimate on the Day; Post-Earnings: The Stock Gains 9.41% in the Current UpdateRevenue Inflection Point - Vinanet
Beam (BEAM) Today: Adds 6.91% to Close at $28.41 on the Day; Range Check: Price Remains Between $26.99 Support and $29.83 Resistance in the Available RecordRVOL Spike - Vinanet
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpShould You Buy? - MarketBeat
Alphabet Inc. Purchases New Shares in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics (BEAM) Edges Higher as Gene Editing Sector Draws Fresh AttentionCash Secured Put - Vinanet
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake - Stock Titan
Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position - Stock Titan
Equities Analysts Offer Predictions for BEAM Q3 Earnings - MarketBeat
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM) - simplywall.st
Weekly Recap: H1 2026 financials and BEAM-302 pivotal cohort dosing - TradingView
Beam Therapeutics Inc. $BEAM Shares Acquired by Janus Henderson Group PLC - MarketBeat
0.24%
1.67%
大文字化:
|
ボリューム (24 時間):